The QualityStocks Daily Newsletter for Tuesday, August 24th 2010 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters


MicrocapVoice (ADAC)


Stock traders chat (MSOA)


StockEgg (CAEI)

The QualityStocks Daily

Pro-Pointer, Inc. (PPII)

Micro Stock Profit, Beacon Equity Research, Penny Stock Finder, Stock Preacher, and NY Stock Report reported today on Pro-Pointer, Inc. (PPII), and we are highlighting the Company as "One to Watch", here at the QualityStocks Daily Newsletter. ‏

Pro-Pointer, Inc., through their wholly owned subsidiary Coenzyme-A Technologies, Inc., is a company that has applied new technology to the formulation and manufacture of a series of proprietary products. These products address nutritional deficiencies that result from the stress of modern day living, chemical imbalances within the body, and the deleterious effects of aging.

Coenzyme-A is the first nutraceoutical manufacture and utilization of cellular Coenzyme-A (The Master Coenzyme). Coenzyme-A contains a specific set of substrates. The design of these is to assist the body in converting fats, carbohydrates and proteins into energy at the cellular level.

Last week, Pro-Pointer, Inc., through their subsidiary Coenzyme-A Technologies, Inc., announced their Coenzyme-A™ “MODULATOR MATRIX V.” This proprietary nutraceutical formula addresses the symptoms of perimenopausal and menopausal women. With the ever-rising demand for products that can naturally address and effectively correct the symptoms of these conditions, the Company believes that this Coenzyme-A development represents a market value well exceeding $5 million in annual revenues.

Yesterday, Pro Pointer, Inc., through Coenzyme-A Technologies, Inc., announced their latest proprietary formulation, the COENZYME-A “Body Energizer Drink”™. The drink formula contains a balanced combination of active nutritional components, cognitive enhancers and cellular energy promoting nutrients, immune system boosters and detoxifying agents.

Today, Pro-Pointer, Inc., via Coenzyme-A Technologies, Inc., announced the introduction of their latest Nutraceutical development, the “MODULATOR MATRIX I” formula, which is designed to help the individual user cope effectively with today’s stress and anxiety syndromes. Coenzyme-A Technologies, Inc. independently developed the proprietary Coenzyme-A nutraceutical product “MODULATOR Matrix I” that naturally addresses hormonal imbalances.

Nickolaos D. Skouras, Ph.D., President of Coenzyme-A Technologies, Inc., explains that both stress and anxiety can cause a cascade of biological reactions that occur in the brain. An over stimulation of the Hypothalamic-Pituitary-Adrenal axis, over time, can damage the immune system and cause a variety of health issues. Current studies also show that the metabolic enzyme (Coenzyme-A) plays a major role in the body’s ability to cope with stress, anxiety, and depression and further strengthen the immune system.

We're keeping an eye on Pro-Pointer, Inc. (PPII), and we're tracking them on our radar screens as "One to Watch", here at the QualityStocks Daily Newsletter.

Pro-Pointer, Inc. (PPII) closed today’s trading at $0.13, up 18.18%, on 3,978,919 volume with 616 trades. The stock’s average daily volume over the past 60 days is 39,967 with a 52-week low/high of $0.025/$0.795. ‏

HealthWarehouse.com, Inc. (HEWAD)

Today we are highlighting HealthWarehouse.com, Inc. (HEWAD) as "One to Watch", here at the QualityStocks Daily Newsletter.
‏HealthWarehouse.com, Inc. is a leading retail mail-order pharmacy with a mission to provide affordable healthcare to every American by eliminating inefficiencies in the drug distribution chain. HealthWarehouse.com trades on the OTC Bulletin Board and has their corporate headquarters in Cincinnati, Ohio.

HealthWarehouse.com offers 300 prescription drugs for $3.50 with 100 percent free shipping. The Company is a 2009 winner of the BizRate Circle of Excellence Award for outstanding customer satisfaction and service. They have become one of the fastest growing online pharmacies in the United States and are licensed in 49 states. The Company only sells drugs that are FDA-approved and legal for sale in the United States.

HealthWarehouse.com, Inc.’s operations center around a state-of-the-art pharmacy. This pharmacy is capable of handling more than 3,000 prescriptions per day. The Company currently services more than 70,000 unique customers.

The Company also offers 90-day returns with no restocking fees, handles defective product returns to the manufacturer, and refers customers to competitors when a product is out of stock. All products ship from their 16,000 square foot warehouse in Cincinnati. Their centralized location allows their products to reach 80 percent of the U.S. within 2 to 3 days.

On August 17, 2010, HealthWarehouse.com, Inc. announced their financial results for the second quarter ended June 30, 2010. During the quarter, their quarterly net sales increased 106 percent to $1.77 million, up from $858,443, compared to the same period in 2009. The sales were driven by growth in prescription and business-to-business customers.

Selling, general and administrative expenses (SG&A) increased by $428,861 for the three months ended June 30, 2010 compared to the same period in 2009. Net loss for the three months ended June 30, 2010 increased 64 percent to $649,329, as compared with a net loss of $396,271 for the same period in 2009. The increase in SG&A expenses and net loss was mainly due to the expansion of resources to handle growth in prescription sales.

Lalit Dhadphale, President and CEO of HealthWarehouse.com, said, “Consumers are becoming increasingly savvy at managing their prescription drug costs as unemployment remains high and insurance benefits erode for those who are employed. We remain committed to providing consumers relief from high prescription drug costs at a time when they need it most.”

We have HealthWarehouse.com, Inc. (HEWAD) locked on our radar screens as "One to Watch", here at the QualityStocks Daily Newsletter.‏

HealthWarehouse.com, Inc. (HEWAD) closed Tuesday’s trading session at $2.75, on no volume. The stock’s average daily volume over the past 60 days is 932 with a 52-week low/high of $1.20/$4.00.‏

Adama Technologies Corp. (ADAC)

Microcap Voice, HotOTC.com, StockEgg.com, Stock Marketing Inc., Cool Penny Stocks, Stock Rich, Penny Invest, All Penny Stocks and Momentum Traders reported earlier on Adama Technologies Corp. (ADAC), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Israel, Adama Technologies Corp. is a "Brownfield Remediation" company. The Company's patented technology is the foundation of their operations. The technology successfully treats all Resource and Recovery Act (RCRA) and Universal Treatment Standards (UTS) metals. This technology successfully completed the U.S. (EPA) "SITE" program and is available for commercial use. Adama Technologies Corp. trades on the OTCBB.

Brownfields are sites affected by the former uses of the site or surrounding land. These sites are derelict or underused, and may have contamination problems. Management of contaminated land means looking for ways to manage or eliminate risks, however, the primary objective of Brownfield redevelopment is the reuse of the land and the reintegration of the properties into the economic cycle.

Adama Technologies Corp. utilizes their $60,000,000 patented MBS (Molecular Bonding System) technology. Adama commitment is to providing long-term permanent solutions to hazardous heavy metal waste problems. Their MBS technology successfully treats metals including arsenic, cadmium, chromium, lead, mercury, and many others. In addition, this technology has the ability to treat difficult waste streams along with being able to treat multiple metals with different solubility points.

Applications for the Company's technology include soils, sludge's, ashes, baghouse dusts, and barrel wastes. The MBS technology has major cost advantages over hazardous waste landfill and alternative remedial technology options. There are an estimated 450,000-plus Brownfields in the United States. Cleaning up and reinvesting in these properties increases local tax bases, facilitates job growth, and utilizes existing infrastructure. It also takes development pressures off undeveloped, open land, and improves and protects the environment.

Adama Technologies Corp. announced, in July of 2009, that they successfully consummated the acquisition of the license for the unique Technology. The technology is the soil remediation technology, which utilizes a solid phase chemical stabilization process. Toxic metals convert rapidly and permanently to non-hazardous, insoluble, non-leachable states. This makes it an ideal and cost effective process for Brownfield reclamations. Adama's acquired Technology has successfully undergone the U.S. EPA's Multiple Extraction Procedure (MEP) laboratory testing. This testing simulates one thousand years of exposure to weather elements, to verify the Technology's effectiveness.

Last month, Adama announced that in conjunction with the Israeli Environmental Office, they will conduct a major pilot program involving utilizing their licensed MBS technology to remediate approximately 1,000 tons of soil (brownfield) which was the site of a battery plant. The site is considered one of the most contaminated sites in Israel. This project makes Adama a key player in the Israel brownfield remediation market that is estimated as high as $3B.

Today, Adama Technologies announced that they entered into negotiations with a privately held clean tech company based in Israel. The company holds approximately $4 million in assets and expects to generate revenue of approximately $10 million in 2011. This merger would provide Adama Technologies Corp. a variety of benefits. These include increased cash flow, revenue, a broadened product portfolio and access to their existing and growing client base.

Adama Technologies Corp. (ADAC) closed Tuesday’s trading session at $0.0103, up 347.83%, on 24,693,089 volume with 584 trades. The stock’s average daily volume over the past 60 days is 274,505 with a 52-week low/high of $0.0021/$0.15.

Deltron Inc. (DTRO)

Penny Stock Club and Microcap Voice reported this month on Deltron Inc. (DTRO), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Deltron Inc. engages in acquiring profitable businesses with strong management teams, substantial revenue, and established market positions. The Company looks to take advantage of unique opportunities to drive company growth and shareholder value. Deltron is targeting additional strategic operations in the commercial and recreational diving field as well as complimentary manufacturing, distribution, and service sector businesses with strong management teams willing to stay on and participate in Deltron Inc.'s growth. Deltron has their corporate headquarters in Garden Grove, California.

One of the Company's wholly owned subsidiaries is Blu Vu. They are a developer of proprietary closed circuit rebreather technology and components. These enable commercial and recreational divers to go deeper, stay underwater longer, and recover faster.

The Blu Vu Deep Oil and Gas Exploration division has designed and developed a critical component of closed-circuit rebreather equipment for commercial and recreational divers. Deltron expects to launch their proprietary bailout valve products in October 2010. They are in discussions with established original equipment manufacturers (OEMs) of rebreather equipment as potential customers. Blu Vu Deep Oil and Gas Exploration is a developer of highly innovative breathing technology for use in extreme environments.

Deltron Inc.'s second wholly owned subsidiary is Elasco. They are an innovator in product manufacturing with a 30-year operating history. Elasco has a diverse customer base and vertically integrated production facility in Garden Grove, California. The Elasco subsidiary recently developed proprietary polyurethane formulations made from renewable resources that significantly reduce the carbon footprint of manufactured products.

On August 10, 2010, Deltron, Inc. announced that their Elasco, Inc. manufacturing subsidiary has enabled Sector 9, a leading manufacturer of skateboards and apparel, to go green by supplying eco-friendly skateboard wheels. Elasco formulates and manufactures Biothane brand polyurethane wheels made with soybean-based polyols for Sector 9. Sales of Elasco’s high performance soy-based wheels have increased significantly this year.

Henry Larrucea, Deltron CEO, commented: “When Elasco developed proprietary formulations to produce polyurethane wheels using soybean polyols, Sector 9 seized the opportunity to be the first skateboard company to offer more sustainable wheels. Increasing sales this year show that the ‘green’ wheels have strong appeal for environmentally conscious customers including surfers, skateboarders and the broader youth market.”

Deltron Inc. (DTRO) closed today’s session at $0.0045, up 114.29%, on 1,574,660 volume with 31 trades. The stock’s average daily volume over the past 60 days is 3,293,534 with a 52-week low/high of $0.001/$0.12.

Neurocrine Biosciences Inc. (NBIX)

Greenbackers, FeedBlitz, Daily Markets, OTC Picks, Stock Traders Chat, Momentum Traders, SmallCap Network and DrStockPick.com reported earlier on Neurocrine Biosciences Inc. (NBIX), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Neurocrine Biosciences, Inc. is a biopharmaceutical company that trades on the NASDAQ Global Select Market. The Company focuses on neurological and endocrine diseases and disorders. They have a diversified pipeline with compounds in all phases of clinical development. Neurocrine Biosciences Inc. has their headquarters in San Diego, California.

The Company's product candidates address some of the largest pharmaceutical markets in the world. These include endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome and other neurological and endocrine related diseases and disorders.

Neurocrine Biosciences pipeline includes GnRH Antagonists. They are conducting a third Phase IIb trial known as the Tulip Petal Study or the 703 Study.  This trial consists of four arms, elagolix 150mg once daily, elagolix 250mg once daily, Prostap SR3.75mb® (Lupron), and placebo.

Their pipeline also includes Corticotropin Releasing Factor (CRF1) Receptor Antagonists. The CRF collaboration between Neurocrine and GSK identified multiple unique high affinity and selective antagonists for the CRF1 receptor. They are currently in clinical development for mood disorders and IBS.

In addition, the Company's pipeline includes Urocortin 2 for congestive heart failure (CHF). Neurocrine Biosciences licensed urocortin 2 to expand further the Company's franchise in corticotropin-releasing factor (CRF) research. Neurocrine's Research Group continues to advance novel small molecule compounds into clinical development.

Their scientists are focusing on developing small molecule antagonists against G-protein coupled receptors. The Company's chemists, pharmacologists and biologists work to create new solutions to unmet medical problems necessary to deliver one new drug candidate every 12 months.

On July 28, 2010, Neurocrine Biosciences, Inc. announced their financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the Company reported a net loss of $5.2 million, or $0.09 per share, compared with a net loss of $15.3 million, or $0.39 per share, for the same period in 2009. For the six months ended June 30, 2010, the Company reported a net loss of $13.8 million, or $0.27 per share, as compared to $34.9 million, or $0.90 per share per share, for the same period last year.

Neurocrine Biosciences Inc. (NBIX) closed Tuesday’s trading session at $5.62, up 0.72%, on 411,186 volume with 1,913 trades. The stock’s average daily volume over the past 60 days is 856,143 with a 52-week low/high of $1.94/$6.64.

Contango Oil & Gas Co. (MCF)

We are highlighting Contango Oil & Gas Co. (MCF), here at the QualityStocks Daily Newsletter.

Founded in 1986, Contango Oil & Gas Co. explores for and produces oil and natural gas. They do this primarily offshore in the Gulf of Mexico. Contango Operators, Inc., their wholly owned subsidiary, acts as operator on certain offshore prospects. Contango Oil & Gas Co. trades on the NYSE Amex and they have their headquarters in Houston, Texas.

The Company is working to build Contango by outsourcing as much as possible. Contango Oil & Gas Co. focuses exclusively on only one small link in the value chain. This is the funding and drilling of an exploratory well for reserves. Therefore, to the maximum extent possible, they outsource everything else.

Contango Oil & Gas Co. bases their exploration strategy on two core beliefs. One is that the only competitive advantage in the commodity-based natural gas and oil business is to be among the lowest cost producers. The second is that almost all the exploration and production industry's value creation occurs through the drilling of successful exploratory wells.

The Company has their exploration alliance with Juneau Exploration, L.P. (JEX).  This alliance partner shares in the upfront costs and the risk of the Company's exploration prospects. JEX is a private company formed to assemble domestic natural gas and oil prospects. Under their agreement with JEX, JEX generates natural gas and oil prospects and evaluates exploration prospects generated by others. JEX focuses on the Gulf of Mexico, and generates offshore exploration prospects through Contango's affiliated companies, Republic Exploration, LLC (REX) and Contango Offshore Exploration, LLC (COE).

Contango Oil & Gas Co. recently named a new Chief Financial Officer (CFO), taking over duties that had been handled by the CEO. The new CFO, Sergio Castro, is also the Company's treasurer and a vice president. Contango Oil & Gas also named Slava Makalskaya as Vice President and Controller. She joined the Company in March after working at PricewaterhouseCoopers.

Yesterday, Contango Oil & Gas Company updated their capital expenditure budget for the fiscal year ending June 30, 2011. The Company has budgeted to invest approximately $85 million to drill four wildcat exploration wells in the Gulf of Mexico. This is at a cost of approximately $15 million each. They will also drill 15 additional on-shore wells at a cost of approximately $1.5 million each, under their Patara joint venture agreement.

The Company's current production is approximately 89 million cubic feet of natural gas per day and 2,400 barrels of oil per day, or 103 million cubic feet equivalent per day, net to Contango.

Contango Oil & Gas Co. (MCF) closed today at $43.06, up 0.35%, on 52,097 volume.

Liberty Energy Corp. (LBYE)

FeedBlitz reported this month on Liberty Energy Corp. (LBYE), Trader Central, Investor Spec Sheet, Street Insider, Small Cap Network, Street Insider, The Best Newsletters, Another Winning Trade, Stock Research Newsletter, Market FN, Daily Profit, and Investment House did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Liberty Energy Corp. is an independent oil and gas exploration company. Their dedication is to the sourcing and production of fuel supplies in the United States and Europe. The Company has signed agreements to acquire leases and royalties in Texas and Bulgaria. Trading on the OTC Bulletin Board, Liberty Energy Corp. has their headquarters in Houston, Texas.

On October 1, 2009, Liberty Energy entered into a Lease Purchase and Sale agreement to acquire four oil and gas leases in Texas. These four leases have undergone identification as rich oil and gas sites based around numerous geological pay zones. These leases are Dahlstrom, Ratliff, and two at Lockhart Northeast.

The Dahlstrom lease is a single well property. It provides a sustainable quantity of natural gas, as well as holding the Master Meter, tying surrounding wells to the Company's lease and giving potential future revenue from any additional wells drilled or re-entered in the surrounding area. There is also potential for the site to undergo re-entering for workover operations with a view to increasing production.

The Ratliff lease currently houses four wells. They are ready for re-development. The expectation is that three of these will be viable for oil and gas, with the fourth also permitted to be a saltwater disposal facility.

In North-West Bulgaria, Liberty has acquired royalty rights to natural gas wells on the A-Lovech exploration block. This is an area of high quality, low-sulphur natural gas condensate. The primary well, Deventci-R1, sits on a 15-20 sq. km. geological feature known as the West Koynare structure, reaching a total depth of 5,888 meters (19,313 ft.) into the Lower Triassic Alexandrovo formation. It has bottom-hole pressure of approximately 11,500psi. This is the highest pressured gas reservoir to undergo identification in Bulgaria.

Liberty Energy Corp. announced on April 22, 2010, that they started to receive revenue generated by the sale of gas produced from the Dahlstrom Lease, Jackson County, Texas.

On August 19, 2010, Liberty Energy Corp. announced that they entered into a well re-entry program on their #1 well, Dahlstrom Lease in Jackson County. The Dahlstrom #1 re-entry well is on approximately 58 acres of potentially productive sands located above the currently completed interval in the Dahlstrom # 1 well. Liberty intends to re-enter the well, perforate the intervals with potentially productive sands, and increase the level of production of natural gas.

Liberty Energy Corp. (LBYE) closed Tuesday’s trading session at $0.67, up 11.67%, on 1,150 volume with 2 trades. The stock’s average daily volume over the past 60 days is 2,041 with a 52-week low/high of $0.25/$1.50.

Sky Petroleum Inc. (SKPI)

Recently, Stock Guru, Hyper Growth Stock, Stock Traders Chat, Hot OTC, Cool Penny Stocks, Stock Rich, Bull Rally, Microcap Voice, and Stock Source reported on Sky Petroleum Inc. (SKPI), and we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Sky Petroleum, Inc. is an oil and gas exploration company. Their primary focus is to seek opportunities where discoveries can be appraised rapidly and developments advanced through either accessing existing infrastructure or by applying the extensive experience of established joint-venture partners. Headquartered in Austin, Texas, Sky Petroleum, Inc. also plans some higher risk, higher reward exploration prospects. The Company also has offices in Dubai, United Arab Emirates.

Sky Petroleum's vision is to pursue high-impact oil and gas projects that demonstrate potential to evolve into excellent hydrocarbon discoveries. They invest in international exploration and development activities in a prolific offshore oil and gas region in the United Arab Emirates. The Company's core management and technical team comprise proven oil and gas professionals. These professionals have extensive international experience in all aspects of exploration, operations, and venture capital markets. Sky Petroleum, Inc. believes that their financial participation in the infill-drilling program on targets situated in the Mubarek Field will provide the basis for near-term cash flow and growth for the Company.

The Mubarek Field is a producing field. It offers full access to pipeline facilities and transport infrastructure. The Ilam/Mishrif reservoir in the Mubarek field has a long history of development dating back to the early 1970s. The first commercial oil was produced in mid-1974 in the Mubarek Field.

The Field is 50 kilometers offshore, north-north west of Sharjah, in 200 feet of water. There are two producing intervals, the aforementioned Ilam/Mishrif light oil reservoir at 12,500 feet and the deeper Thamama gas condensate at 13,500 feet. Sky Petroleum believes that this program will achieve their objective to exploit and maximize the potential of the substantial untapped oil reservoirs known to exist in the Ilam/Mishrif reservoir.

Sky Petroleum, Inc. announced in June that they completed and executed a Production Sharing Contract. It covers three exploration blocks, Four, Five, and Dumre in the Republic of Albania. His Excellency Dritan Prifti, Minister of Economy, Trade and Energy for Albania and Mr. Karim Jobanputra, President and CEO of Sky Petroleum attended the official signing ceremony in Tirana, Albania on June 24, 2010.
Sky Petroleum Inc. has been granted exclusive rights under the Production Sharing Contract to three exploration blocks totaling approximately 5,000 km2 (1.2 million acres). This represents approximately 20 percent of the landmass of Albania. The Company will also have access to more than 1,200 km of 2-D seismic data, in addition to the exploration rights.

On August 18, 2010, Sky Petroleum, Inc. announced the appointment of Oliver J. Whittle to their Board of Directors. Mr. Whittle received appointment by the Board; he will act as interim advisor before full commencement on October 1, 2010. Mr. Whittle has more than forty years of international banking experience and is currently the Chief Executive Officer of Raiffeisen Bank Albania, the largest bank in the country.

Sky Petroleum Inc. (SKPI) closed Tuesday’s trading session at $0.60, up 13.42%, on 532,041 volume with 100 trades. The stock’s average daily volume over the past 60 days is 353,638 with a 52-week low/high of $0.06/$0.54.

The QualityStocks Company Corner

Simulated Environment Concepts, Inc. (SMEV)

The QualityStocks Daily Newsletter would like to spotlight Simulated Environment Concepts, Inc. (SMEV). Today, Simulated Environment Concepts, Inc. closed trading at $0.0150, up 15.38%, on 120,000 volume with 4 trades. The stock’s average daily volume over the past 60 days is 180,646 with a 52-week low/high of $0.001/$0.07.

Simulated Environment Concepts, Inc. (SMEV) announced today that Aspire Consulting, Ltd., a UK based firm specializing in fitness and weight loss, has engaged SpaCapsule for its Vibralife Fitness Clinic and distribution model for the UK market.

Simulated Environment Concepts, Inc. (SMEV) is focused on manufacturing and distributing their patented SpaCapsule® as well as continued innovation in the areas of anti-aging, cosmetics, relaxation, cellulite reduction, and weight loss. Finding use in numerous environments such as relaxation centers, golf clubs, ski lounges, gyms, and health clubs, the SpaCapsule® provides next generation de-stressing and relaxation.

The company’s founders, Dr. Ella Frenkel and Dr. Ilya Spivak, initially capitalized Simulated Environment Concepts Inc. with several million dollars of their own money. With this initial investment, the company worked on, and succeeded in developing, the sleek and stylish looking pressurized dry water massage relaxation station.

SpaCapsule® is a full body massage, aromatherapy, audio and video entertainment system. The capsules are fused with advanced modern technology and healing methods of aromatherapy and audiovisual relaxation techniques, incorporating proprietary water-jet and pressure-jet technology that requires no on-site plumbing. Weighing approximately 500 lbs, the capsule only requires standard electric service.

Simulated Environment Concepts, Inc. (SMEV) anticipates progressive and consistent growth over the next six years. With individuals spending billions of dollars on de-stressing, weight loss, anti aging, cosmetics, massage and physical rehabilitations, the company is in a position to experience explosive growth from current levels. Disclaimer

Simulated Environment Concepts, Inc. Blog

Simulated Environment Concepts, Inc. News:

Simulated Environment Concepts Attains Pink Sheets Current Information Status

Simulated Environment Concepts Projects European Sales Increase Due To French Distributor's Fast Pace

Simulated Environment Concepts Continues Global Expansion With Another Multi-Million Dollar International Production Deal by Way of United Arab Emirates' Distributor

Cellceutix Corp. (CTIX)

The QualityStocks Daily Newsletter would like to spotlight would like to spotlight Cellceutix Corp. (CTIX). Today, Cellceutix Corp. closed trading at $0.45, for no change. The stock’s average daily volume over the past 60 days is 3,496 with a 52-week low/high of $0.23/$1.01.

Cellceutix Corporation (CTIX) announceD substantial progress on the toxicology studies for Kevetrin™, the Company's compound for the treatment of multi-drug resistant cancers. In preparation for the Investigational New Drug (IND) filing, Cellceutix is engaging additional consultation to move forward towards clinical trials with Kevetrin.

Cellceutix Corporation (CTIX) an emerging bio-pharmaceutical company, is in the early stages of receiving an influx of media attention and widespread notoriety within the pharmaceutical industry due to the promising results shown during the early development of a compound for the treatment of autism, KM-391, and the approaching Phase 1 clinical trials of Kevetrin™, the company's compound for the treatment of drug-resistant cancers. In addition to these two, Cellceutix currently manages a portfolio of six other promising compounds.

KM-391, a 100% novel compound, is revolutionary in that it addresses the core issues of autism, unlike the pharmaceuticals presently on the market which merely treat the symptoms that result from autism. Preliminary testing of KM-391 revealed that test animals showed a significant increase in serotonin uptake compared to controls with noticeable and measurable positive therapeutic changes. Cellceutix is rapidly developing KM-391 in response to the public outcries received by the company since the results of early testing had been made publicly available.

Kevetrin, Cellceutix's flagship product, is nearing Phase 1 clinical trials on humans with FDA regulated pre-clinical testing completed and the data being properly compiled for the IND application. While most cancer treatments today are derivatives of other compounds, Kevetrin is completely unique. Multidrug resistance, the principal mechanism by which strains of cancer develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapy today and represents a huge need for novel cancer treatments.

Kevetrin has been extensively studied in animal models of lung, breast, and colon cancers, targeting carcinoma strains that have proven resistant to standard therapies available on the market today with the results showing greater tumor growth delay than present therapies and strong efficacy in mouse models with increasing dosages. A successful drug for the treatment of drug-resistant cancers is purported to generate billions of dollars in annual revenues.

The Company has procured leading figures in the health and science arenas to lead its development efforts. The officers and advisors of Cellceutix include pioneers in the fields of cancer and genetics, as well as those who have been integral to mergers, acquisitions and the generation of exorbitant revenues through ground breaking therapies while holding high-level executive and research positions at industry giants such as Pfizer and Eli Lilly. Holding over a century of highly relevant experience in the pharmaceuticals industry, the team has been assembled with the specific goal of duplicating these past successes while revolutionizing much needed treatments for today's most challenging diseases. Disclaimer

Cellceutix Corp. Blog

Cellceutix Corp. News:

Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to Filing Investigational New Drug (IND) Application

AllPennyStocks.com News: Drug-Resistant Cancers Now a Focal Point for Progressive Biotechs

AllPennyStocks.com Announces Corporate Write-Up on Cellceutix Corp. (OTCBB:CTIX)

eDOORWAYS Corporation (EDWY)

The QualityStocks Daily Newsletter would like to spotlight eDOORWAYS Corporation (EDWY) Today eDoorways Corporation closed trading at $0.0022, for no change, on 2,105,909 volume with 13 trades. The stock’s average daily volume over the past 60 days is 3,540,983 with a 52-week low/high of $0.0011/$0.16.

eDOORWAYS Corp. (EDWY) is committed to solving lifestyle problems for consumers while driving traffic to suppliers and service providers who offer innovative merchandise and solutions. The company has the potential to completely change the future landscape of business by offering a unique and comprehensive service that saves consumers valuable time and money. By uniting a consumer with the larger global consumer community, retailers, and manufacturers in an effective new way, eDOORWAYS promotes “dynamic” commerce, as opposed to the static model currently in existence.

The Company plans to capitalize on several emerging new trends. These newly created opportunities include: the large success of Web 2.0 Internet community service offerings such as MySpace, the movement towards niche marketing and targeted advertising, the introduction of new technologies that enable instantaneous, online presentation of information, and the rising consumer preference for using the Internet to gain information before making purchasing decisions.

eDOORWAYS plans to introduce local services using a city-by-city strategy that will minimize capital requirements, reduce staffing requirements, and optimize generated revenues. Ten major cities are targeted for launch in the first year. Advertising, PR campaigns and viral word-of-mouth will be used to give a public presentation to experts as well as educate the market.

The key benefits offered to consumers include a higher level of engagement with vendors, trusted information from other consumers, and superior customer service. Revenues will be generated through advertising placement fees, premium services, preferential placement fees, and a percentage of sales transactions. eDOORWAYS' progressive vision and professional management team makes it an attractive investment opportunity. Disclaimer

eDOORWAYS Corporation Blog

eDOORWAYS Corporation News:

In A New Audio Interview at SmallCapVoice.com, Dr. Ramiro Jordan Discusses the New Technology from eDoorways Corporation

eDoorways Files Form 15, Focuses on Securing Additional Revenue Opportunities

eDoorways - CorkSport, Sign First PowerKey Channel Deal

Uranium Energy Corp. (UEC)

The QualityStocks Daily Newsletter would like to spotlight Uranium Energy Corp. (UEC) Today, Uranium Energy Corp. closed trading at $2.50 on 274,629 volume with 871 trades. The stock’s average daily volume over the past 60 days is 359,756 with a 52-week low/high of $2.11/$4.16.

Uranium Energy Corp. (UEC) is a U.S.-based exploration and development company focused on near-term uranium production in the U.S. The company’s operations are managed by professionals who have earned a reputable profile through many decades of hands-on experience in the key facets of uranium exploration, development and mining.

Uranium Energy controls one of the largest databases of historic uranium exploration and development in the nation. Using this knowledge base, the company has acquired and is advancing exploration properties of merit throughout the southwestern U.S., a region known as being the most concentrated area for uranium mining in the United States.

The Company’s fully licensed and permitted Hobson processing facility is central to all of its projects in South Texas. Well financed to execute on its key programs, Uranium Energy's Palangana is-situ recovery project is fully permitted, and its Goliad in-situ recovery project is in the final stages of mine permitting for production.

The company’s strategy of acquiring exploration databases and leveraging those databases to generate acquisition targets has proven to be effective thus far. With plans to continue aggressively pursuing this strategy, Uranium Energy Corp is well positioned to capitalize on the world’s first significant alternative energy boom. Disclaimer

Uranium Energy Corp. Blog

Uranium Energy Corp. News:

Uranium Energy Corp Issues Mid-Year Shareholder Report

Uranium Energy Corp Announces Results of AGM

Uranium Energy Corp Announces Historical Resource of 1.5 Million Pounds eU3O8 at the Company's Salvo Project in South Texas

Micro Identification Technologies (MMTC) Continues Scale Up for MIT 1000 Pathogen ID System

When Micro Identification Technologies Inc., developer of the revolutionary MIT 1000 laser-based microbial identification system, indicated earlier that they were on track to begin quantity deliveries of their system in 4Q of 2010, they added something of an admonition. MIT’s Chairman, Michael Brennan, said that the company needs “to increase our system support and microbiological research capabilities in conjunction with supporting the food industry’s obvious safety requirements.” It was a way of saying that, although the future is bright, the company has more work to do.

There’s little question of a growing interest in their product, since it provides companies and agencies a much quicker and more cost effective way of identifying potentially harmful bacterial contamination before it spreads. To translate interest into dollars, the company is moving forward with plans for financing and production.

Today, with food safety concerns becoming front page news, MIT’s growth preparations are well under way. Underpinning these moves is the company’s important equity placement agreement along with their recent manufacturing contract with OSI Optoelectronics to produce its systems. MIT has already produced the MIT 1000 in limited quantities and has had several distinguished users, including the U.S. Department of Agriculture, Japanese Ministry of Food Safety, University Putra Malaysia, and various local contract laboratories. Results have been encouraging enough to begin working towards scaled up production.

With the FDA being given broader powers to oversee the way food is grown, harvested, processed, and delivered, the timing couldn’t be better for Micro Identification Technologies. The Washington Post recently noted “These actions follow a wave of food-borne illnesses over the past three years, involving products as varied as spinach, peanuts, cookie dough and meat, which has shaken consumer confidence and made the issue a priority for congressional leaders and the White House. Food illnesses sicken one in four Americans and kill 5,000 each year, according to government statistics. Tainted food has cost the food industry billions of dollars in recalls, lost sales and legal expenses. Under the legislation, the FDA will get new enforcement powers and be able to impose beefed-up civil and criminal penalties. One provision allows the FDA to declare food ‘adulterated’ simply if the grower or manufacturer has failed to follow safety standards, regardless of whether the food is actually tainted.”

Cellceutix Corp. (CTIX) Wraps Up Toxicology Studies as Human Trials Near for Kevetrin

Cellceutix Corp. announced today that they have received nearly all the data regarding the toxicology studies for Kevetrin™, the Company’s flagship compound for the treatment of multi-drug-resistant cancers. The remaining data is expected within two or three weeks. This data is the final information required for the Investigational New Drug Application (IND) to be prepared and submitted to the U.S. Food and Drug Administration. In preparation for the filing, Cellceutix has engaged additional consultation to bring Kevetrin to human trials.

George Evans, CEO of Cellceutix, commented, “We are continuing to hit our targets at or ahead of schedule with Kevetrin. The pre-clinical data to date has been extremely encouraging and we expect that these final data are going to fall right into line.” Mr. Evans continued, “We are well aware of the significant impact Kevetrin can provide to patients in need if Kevetrin can perform in human trials as it has in the pre-clinical research. We are presently organizing the team for the IND and doing all possible preparation in order to submit the filing quickly once the final toxicology data is in our hands.”

“I have been closely involved in the development of several successful compounds in my 30 years in the industry and am extremely encouraged by the data that Kevetrin has produced,” stated Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “The completion of pre-clinical studies creates a great deal of excitement for our team as we are anxious to see Kevetrin being utilized as a human therapy in the near future.”

In a recent interview on CEOCFOinterviews.com, Leo Ehrlich, CFO of Cellceutix is quoted as saying, “Our chief scientific officer, who developed our cancer drug, was a group leader of cancer research at Eli Lilly (NYSE: LLY). He was the key developer of two blockbuster cancer drugs named Alimta and Gemzar, which generate billions of dollars in sales.” The history of CEO George Evans and his extensive experience as General Counsel at Pfizer, coupled with the experiences of Dr. Menon and the rest of the Advisory Board, should make many industry leaders take notice of Cellceutix.

The pre-clinical research of Kevetrin appears to have moved smoothly and quickly with extremely promising data. In the biotechnology world, companies are very careful not to divulge too much information or makes statements that can be misleading as there is always a possibility that drugs will fail as research and testing continues. This makes complete sense from every legal aspect. But, it should not go without recognition that the team at Cellceutix has a very distinguished history.

More due diligence on Cellceutix Corporation, the compounds in the pipeline and the investment opportunity presented can be found on the Company’s website at www.cellceutix.com.

Simulated Environment Concepts, Inc. (SMEV) Announces Expansion of Vibralife Fitness Program

Simulated Environment Concepts, Inc. (SE Concepts), makers of the high pressurized dry water massage and wellness equipment – SpaCapsule, announced this morning that Aspire Consulting, Ltd., a UK based firm specializing in fitness and weight loss, has engaged the company for its Vibralife Fitness Clinic and distribution model for the UK market.

“SpaCapsule does much more than promote affordable and non-intrusive relaxation,” stated Dr. Ella Frenkel, CEO and President of Simulated Environment Concepts, Inc. (SE Concepts). “SpaCapsule assists in the areas of fitness, weight loss and cellulite reduction when used regularly. We are very excited that Aspire Consulting is placing our units as a front-runner in their Vibralife fitness concept.”

Terms of the agreement call for twelve SpaCapsule units to be part of Aspire and Vibralife’s fitness concept. SE Concepts has already shipped the first order of six, with plans to ship the remainder before the end of next month.

Stewart Brown, President of Aspire Consulting, Ltd., commented, “We have searched diligently in an attempt to select the best equipment for our franchise. SpaCapsule fit our concept perfectly. We were amazed by the professional response and strategic experience of the SE Concepts team. The units received are already hard at work at our Vibralife location and the response from patrons is very uplifting. Please visit http://www.vibralife.co.uk/pages/spa_capsules.html to get a feeling for how the SpaCapsule is being used and positioned by us.”

Although this agreement isn’t the first time SE Concepts entered into the European market, it does signify the company’s continued expansion abroad and the depth of its growing relationships with European distributors. According to sources, Aspire plans to incorporate the SpaCapsule into a total fitness program similar to that of Lady Fitness in France as well as delve into the medical distribution of SpaCapsule as SE Concepts soon broadens the reach of its technology with the PTjetCapsule (designed for Physical Therapy Centers worldwide).

“The contract with Aspire Consulting marks a new milestone in our European distribution model,” said Dr. Ilya Spivak, Marketing Director at SE Concepts. “Though the UK was one of the first European countries to embrace our SpaCapsule aquamassage unit, this is the first time that we have a UK partner with a vision and true business plan. We are working very closely with the team at Aspire to assist them with sales and technical support to ensure our joint vision comes to fruition.”

Adama Technologies Corp. (ADAC) in Talks to Merge with Privately-Held Clean Tech Company

Adama Technologies Corp. is a brownfield remediation company whose foundation lies in its patented technology. The company’s technology successfully treats all Resource and Recovery Act (RCRA) and Universal Treatment Standards (UTS) metals. Adama’s technology has successfully completed the US Environmental Protection Agency (EPA) “SITE” program and is ready for commercial use.

The company today announced that it has entered into negotiation with a privately-held clean tech company based in Israel. The company in question holds approximately $44 million in assets and expects to generate revenue of $10 million in 2011. This proposed merger would provide Adama a host of benefits including revenue, increased cash flow, a broadened product portfolio and access to the Israeli company’s existing and growing client base.

Adama realizes that negotiations with a company of this magnitude represents an enormous leap forward for the company. The company hopes to enter the Letter of Intent stage in the next several weeks, at which time it will release more details about the merger. The CEO of Adama Technologies, Aviram Malik, stated, “With adding this merger to Adama revenue projection of $8 million in 2011, as the company pilot plan with the EPA in its last stages, we are fully cognizant of the impact of this type of merger on our company and its shareholders.”

Today’s market action in the stock seems to back up Mr. Malik’s words. Adama Technologies closed trading at $0.0103, up $0.008 or over 347% for the day. The volume was massive at over 24 million shares, well above the daily average of about 143,000 shares. For more information of Adama Technologies, please visit the company’s website at www.adama-tech.com.


Sponsors of the Day


The QualityStocks Public Company Sponsor News

Micro Identification Technologies Inc. (MIT) (MMTC) MIT Initiates Expansion Plans Enabled by Recently Completed Manufacturing and Financing Agreements



About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-374-1336